Literature DB >> 32394815

Treatment of Déjerine-Roussy syndrome pain with scrambler therapy.

Paul J Christo1, David O Kamson1, Thomas J Smith1.   

Abstract

Aim: Déjerine-Roussy syndrome or central thalamic pain can be devastating, and treatment with drugs and even deep brain stimulation can be unsatisfactory. Scrambler therapy is a form of neuromodulation that uses external skin electrodes to send a 'non-pain' signal to the brain, with some success in difficult-to-treat syndromes such as neuromyelitis optica spectrum disorder. We used scrambler therapy to treat a patient with 6 years of disabling Déjerine-Roussy syndrome pain.
Methods: A 56-year-old man received multiple daily then monthly treatments with electrode pairs placed just above the area of distal pain. Each treatment was for 40 min.
Results: His allodynia and hyperalgesia resolved within 10 min, and his pain score fell to almost zero after 30 min. Months later, he resumed normal activity and is off all his pain medications. No side effects were noted.
Conclusion: Scrambler therapy appeared to reverse 6 years of disabling pain safely and economically, and continues to be effective. Further multi-institutional trials are warranted for this rare syndrome.

Entities:  

Keywords:  Dejerine–Roussy syndrome; central pain; neuromodulation; neuropathic pain; scrambler therapy; thalamic pain

Mesh:

Year:  2020        PMID: 32394815     DOI: 10.2217/pmt-2019-0065

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  3 in total

1.  Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation.

Authors:  Thomas J Smith; Anna Ferguson; Marina Baretti; Mark Yarchoan
Journal:  Mayo Clin Proc       Date:  2021-05       Impact factor: 11.104

2.  Scrambler Therapy for the Treatment of Pain in Schwannomatosis.

Authors:  Tyler Murphy; Michael Erdek; Thomas J Smith
Journal:  Cureus       Date:  2022-03-13

3.  Use of Scrambler Therapy in the Treatment of Amyloidosis Neuropathic Pain.

Authors:  Joann B Hunsberger; Vaishali Rathee; Thomas J Smith
Journal:  J Palliat Med       Date:  2021-07-27       Impact factor: 2.947

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.